MedPath
HSA Approval

ABALAM ABACAVIR SULFATE & LAMIVUDINE TABLETS 600/300 MG

SIN15864P

ABALAM ABACAVIR SULFATE & LAMIVUDINE TABLETS 600/300 MG

ABALAM ABACAVIR SULFATE & LAMIVUDINE TABLETS 600/300 MG

December 2, 2019

MEDICELL PHARMACEUTICAL (S) PTE. LTD.

MEDICELL PHARMACEUTICAL (S) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMEDICELL PHARMACEUTICAL (S) PTE. LTD.
Licence HolderMEDICELL PHARMACEUTICAL (S) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

J05AR02

lamivudine and abacavir

Manufacturer Information

MEDICELL PHARMACEUTICAL (S) PTE. LTD.

HETERO LABS LIMITED

Active Ingredients

Abacavir Sulfate 702.762 mg eqv. Abacavir

600.0 mg

Abacavir

Lamivudine

300.000 mg

Lamivudine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ABALAM ABACAVIR SULFATE & LAMIVUDINE TABLETS 600/300 MG - HSA Approval | MedPath